3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
19
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
HER2-positive Breast Cancer
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Solid Tumor
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
Radiosurgery
6
Bevacizumab
4
Gentamicins
3
Everolimus
3
Cochlear Implants
3
Lapatinib
2
tozuleristide
1
neratinib
1
icotinib
1
gallium Ga 68 dotatate
1
brigatinib
1
Triamcinolone Acetonide
1
Sufentanil
1
Sirolimus
1
Microsurgery
1
Methylprednisolone
1
Magnetic Resonance Spectroscopy
1
Losartan
1
Head Movements
1
HDAC-42
1
Fluoresceins
1
Fluorescein
1
Exome
1
Endostatins
1
Endoscopes
1
Docosahexaenoic Acids
1
Decision Support Techniques
1
Axitinib
1
Aspirin
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroma, Acoustic
×
neratinib
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled